Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
暂无分享，去创建一个
C. Bokemeyer | E. Van Cutsem | J. Tabernero | B. Melichar | U. Martens | S. Tjulandin | F. Rivera | S. Quaratino | T. Csoszi | I. Kocáková | M. Šmakal | E. Topuzov | R. Orlova | J. Straub | R. Bruns | E. Élez | T. Höhler | T. Csőszi